---
schema_version: "secwatch.filing_event.v1"
accession: "0001737287-22-000074"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2022-10-06T23:59:59+00:00"
generated_at: "2026-06-23T05:06:21.287658+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Allogene initiates Phase 2 ALPHA2 trial of ALLO-501A in r/r LBCL; plans EXPAND trial for ALLO-647

## Summary
- ALPHA2 trial will enroll ~100 r/r LBCL patients with single 120M CAR+ cell dose; primary endpoint ORR.
- EXPAND trial (~70 patients) randomized to assess ALLO-647 contribution to lymphodepletion regimen.
- FDA cleared manufacturing from CF1 using non-Alloy process; Alloy process being implemented at CF1.
- Company plans to seek FDA approval based on ALPHA2 and EXPAND trials assuming favorable outcomes.
- CD19 program update, including longer-term Phase 1 follow-up with Alloy process, expected end of 2022.

## SEC filing metadata
- accession: 0001737287-22-000074
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2022-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000074/0001737287-22-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000173728722000074/allo-20221006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001737287-22-000074
- JSON: https://secwatch.observer/filing/0001737287-22-000074.json
- Plain text: https://secwatch.observer/filing/0001737287-22-000074.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.